• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Perioperative Red Blood Cell Transfusion Is Associated With Adverse Cardiovascular Outcomes in Heart Valve Surgery
CONCLUSIONS: In the analysis of the national cohort, perioperative RBC transfusion during heart valve surgery was associated with adverse cardiovascular outcomes correlated with the volume of RBC transfusion.PMID:36730895 | DOI:10.1213/ANE.0000000000006245
Source: Anesthesia and Analgesia - February 2, 2023 Category: Anesthesiology Authors: Hee Jung Kim Ji Eon Kim Ji Yoon Lee Seung Hyung Lee Jae Seung Jung Ho Sung Son Source Type: research

Laparoscopic adrenalectomy of pheochromocytoma following management of severe aortic stenosis with transcatheter aortic valve replacement under monitored anesthesia care sedation: a case report
Management of a patient with an active pheochromocytoma and severe aortic stenosis remains controversial. Adrenalectomy for a pheochromocytoma poses a high risk for stroke, hypertensive emergency, and mortalit...
Source: BMC Anesthesiology - January 11, 2023 Category: Anesthesiology Authors: Leon Yang, Lauren Hennis, Kevin Patel and Michael A. Saccocci Tags: Case report Source Type: research

Effect of remimazolam on the incidence of delirium after transcatheter aortic valve implantation under general anesthesia: a retrospective exploratory study
ConclusionRemimazolam may benefit TF-TAVI in terms of postoperative delirium; however, its usefulness must be further evaluated in extensive prospective studies.
Source: Journal of Anesthesia - December 4, 2022 Category: Anesthesiology Source Type: research

Perioperative Bleeding Requiring Blood Transfusions Is Associated with Increased Risk of Stroke after Transcatheter and Surgical Aortic Valve Replacement
We aimed to investigate the impact of severe bleeding and use of red blood cell (RBC) transfusion on the development of postoperative stroke after surgical (SAVR) and transcatheter aortic valve replacement (TAVR) from the FinnValve registry.
Source: Journal of Cardiothoracic and Vascular Anesthesia - April 26, 2022 Category: Anesthesiology Authors: Tuomas Tauriainen, Tatu Juvonen, Vesa Anttila, Pasi Maaranen, Matti Niemel ä, Markku Eskola, Tuomas Ahvenvaara, Annastiina Husso, Marko P.O. Virtanen, Eeva-Maija Kinnunen, Sebastian Dahlbacka, Maina Jalava, Mika Laine, Antti Valtola, Peter Raivio, Antti Tags: Original Article Source Type: research

Self-Expanding Versus Balloon-Expandable Valve: Are We at the Cusp of Delivering a Perfect Transcatheter Aortic Valve?
Transcatheter aortic valve replacement (TAVR) has become a leading and dominant treatment alternative to surgical aortic valve replacement (SAVR) for intermediate- and high-risk patients with aortic stenosis.1-5 The follow-up trials for both the core valve, as well as the balloon-expanding valve, showed similar midterm survival and stroke rates in high-risk patients following TAVR versus SAVR.6-8 With the recent results of the PARTNER 3 and EVOLUT low-risk trials, it is evident that, among patients with severe aortic stenosis with low surgical risks, the rates of composite death, stroke, and rehospitalization at 1 year wer...
Source: Journal of Cardiothoracic and Vascular Anesthesia - November 26, 2021 Category: Anesthesiology Authors: Ankit Jain Tags: Editorial Source Type: research

Self-Expanding versus Balloon Expandable Valve – Are we at the Cusp of Delivering a Perfect Transcatheter Aortic Valve?
Transcatheter aortic valve replacement (TAVR) has become a leading and dominant treatment alternative to surgical aortic valve replacement (SAVR) for high- and intermediate-risk patients with aortic stenosis.1 –5 The follow up trials for both the core valve as well as the balloon-expanding valve showed similar mid-term survival and stroke rates in high-risk patients following TAVR vs SAVR.6–8 With the recent results of the PARTNER 3 and EVOLUT low risk trials, it is evident that, among patients with s evere aortic stenosis with low surgical risks, the rate of composite death, stroke and rehospitalization at 1 year was ...
Source: Journal of Cardiothoracic and Vascular Anesthesia - November 26, 2021 Category: Anesthesiology Authors: Ankit Jain Tags: Editorial Source Type: research

Assessment of the left ventricular outflow tract during cardiac anaesthesia with biplane transoesophageal echocardiography: An observational study
BACKGROUND Assessment of left ventricular outflow tract (LVOT) area is a key component of quantification of aortic stenosis and stroke volume. Current international guidelines recommend measurement of the LVOT diameter with two-dimensional (2D) echocardiography and assume a circle. This may lead to erroneous measures of aortic valve area and adversely affect peri-operative decision making. Multiplane orthogonal (biplane) and three-dimensional (3D) echocardiography imaging may allow more accurate calculation of LVOT, aortic valve area and stroke volume. OBJECTIVE To evaluate the shape and area of the LVOT with co...
Source: European Journal of Anaesthesiology - November 19, 2021 Category: Anesthesiology Tags: Haemodynamics Source Type: research

The PARTNER 3 Trial at Two Years: What We Have Learned and What Time Will Tell
Based on data from large, industry-sponsored randomized prospective studies, the US Food and Drug Administration (FDA) has approved both balloon-expandable and self-expanding transcatheter aortic valve replacement (TAVR) devices for use in aortic stenosis patients at low, intermediate, and high risk for surgical aortic valve replacement (SAVR).1-6 High-risk device approval was based on one-year data, which was reasonable due to the actuarial life expectancies of the cohort.1,2 Intermediate-risk approval for the balloon-expandable SAPIEN XT (Edwards Lifesciences, Irvine, CA) system was based largely on data from the Placeme...
Source: Journal of Cardiothoracic and Vascular Anesthesia - May 28, 2021 Category: Anesthesiology Authors: Peter J. Neuburger, Kinjal M. Patel, Prakash A. Patel Tags: Editorial Source Type: research

The PARTNER 3 Trial at 2 Years: What We've Learned and What Time Will Tell
Based on data from large, industry-sponsored randomized prospective studies, the United States Food and Drug Administration (FDA) has approved both balloon-expandable and self-expanding transcatheter aortic valve replacement (TAVR) devices for use in aortic stenosis patients at low, intermediate and high-risk for surgical aortic valve replacement (SAVR).1-6 High-risk device approval was based on 1-year data, which was reasonable due to the actuarial life expectancies of the cohort.1, 2 Intermediate-risk approval for the balloon-expandable Sapien XT (Edwards Lifesciences, Irvine, California) system was largely based on data...
Source: Journal of Cardiothoracic and Vascular Anesthesia - May 28, 2021 Category: Anesthesiology Authors: Peter J. Neuburger, Kinjal M. Patel, Prakash A. Patel Source Type: research

A Case of Successful Treatment of Cerebral Embolism Using Endovascular Thrombectomy Immediately After Transcatheter Aortic Valve Implantation
TRANSCATHETER aortic valve implantation (TAVI) is a less invasive alternative to surgical aortic valve replacement in high-risk patients with severe aortic stenosis. However, there are increasing concerns about the potential complications of TAVI now that its indications have been expanded to include patients with low-to-intermediate surgical risk.1,2 One of the serious complications of TAVI is stroke. It is known that there is an increase in 30-day mortality, rates of respiratory insufficiency and postprocedural delirium, and duration of hospital stay if stroke occurs.
Source: Journal of Cardiothoracic and Vascular Anesthesia - December 17, 2019 Category: Anesthesiology Authors: Shunichi Murakami, Kazuyoshi Ishida, Hideyuki Ishihara, Takayuki Okamura, Tetsuro Oda, Ryo Suzuki, Atsuo Yamashita, Satoshi Yamashita, Hiroshi Kurazumi, Michiyasu Suzuki, Mishiya Matsumoto Tags: Case Report Source Type: research

Left Atrial Thrombus Formation in a Patient With Severe Non-rheumatic Mitral Stenosis After Mitral Valve Repair Receiving Dual Antiplatelet Therapy: A Clinical Challenge
A 60-YEAR-OLD, 88-kg, 165-cm woman presented to a community hospital with heart failure 5 years after mitral valve repair for mitral regurgitation. The patient previously suffered an ischemic stroke and was currently treated with dual antiplatelet therapy. Transesophageal echocardiography revealed severe mitral stenosis with a mean transmitral gradient of 10 mmHg and thickening of the posterior left atrial wall. The patient was then transferred to the authors ’ institution for mitral valve replacement.
Source: Journal of Cardiothoracic and Vascular Anesthesia - June 10, 2019 Category: Anesthesiology Authors: Michael Essandoh, Amir Elhassan, Thomas J. Papadimos, Brandon Pruett, Gregory D. Rushing Tags: Diagnostic Dilemma Source Type: research

Myocardial Protection During Minimally Invasive Mitral Valve Surgery: Is Retrograde Cardioplegia Alone Enough?
Minimally invasive mitral valve surgery is a commonly performed procedure in contemporary cardiac surgery.1-3 The surgical exposure for minimally invasive mitral valve surgery (right anterolateral minithoracotomy) provides very limited access to the aorta and makes myocardial protection with antegrade cardioplegia challenging.1,3 Early experiences used an endo-aortic balloon to administer antegrade cardioplegia, and retrograde cardioplegia was administered through a coronary sinus catheter.3 The endo-aortic balloon approach was associated with complications such as aortic dissection and stroke and has fallen out of favor in some centers.
Source: Journal of Cardiothoracic and Vascular Anesthesia - March 17, 2019 Category: Anesthesiology Authors: Michael Essandoh Tags: Letter to the Editor Source Type: research

Pages: 1  2  3